Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galenica's gross profit for the
six
months ended in Dec. 2025 was CHF605 Mil. Galenica's gross profit for the trailing twelve months (TTM) ended in Dec. 2025 was CHF1,156 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Galenica's gross profit for the
six
months ended in Dec. 2025 was CHF605 Mil. Galenica's Revenue for the
six
months ended in Dec. 2025 was CHF2,140 Mil. Therefore, Galenica's Gross Margin % for the quarter that ended in Dec. 2025 was 28.25%.
Galenica had a gross margin of 28.25% for the quarter that ended in Dec. 2025 => Competition eroding margins
During the past 13 years, the highestGross Margin % of Galenica was 27.94%. The lowest was 24.20%. And the median was 25.64%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Galenica had a gross margin of 28.25% for the quarter that ended in Dec. 2025 => Competition eroding margins
Galenica Gross Profit Related Terms
Galenica Gross Profit Historical Data
* Premium members only.
The historical data trend for Galenica's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALE vs MCK, COR, CAH: Gross Profit Comparison
For the Medical Distribution subindustry, Galenica's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galenica Gross Profit vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Galenica's Gross Profit distribution charts can be found below:
* The bar in red indicates where Galenica's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF1,156 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Galenica (XSWX:GALE) has a Gross Profit of CHF1,156 Mil as of Dec. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Galenica and its competitors.
Is Galenica's Gross Profit too high?
Galenica's current Gross Profit is CHF1,156 Mil. Overall, Galenica has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Galenica's Gross Profit compare to MCK and COR?
Galenica's Gross Profit of CHF1,156 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Distribution company?
A good Gross Profit depends on the Medical Distribution industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Galenica and its competitors. Galenica's current Gross Profit is CHF1,156 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galenica stock overvalued right now?
Based on GuruFocus' analysis, Galenica (XSWX:GALE) is currently considered Fairly Valued. The stock's GF Value™ is CHF86.67, compared to a current price of CHF85.95 — trading 0.8% below its estimated fair value. The current Gross Profit is CHF1,156 Mil. Galenica's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Galenica (XSWX:GALE), the current Gross Profit is CHF1,156 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Galenica (XSWX:GALE) Overvalued in 2026?
Based on GuruFocus' analysis, Galenica stock appears to be undervalued.
The current stock price of CHF85.95 is trading 0.8% below its estimated GF Value™ of CHF86.67.
GuruFocus considers Galenica to be Fairly Valued.
Key valuation signals for XSWX:GALE:
Gross Profit: CHF1,156 Mil
GF Value™: CHF86.67 vs. price of CHF85.95 (0.8% below fair value)
No single metric tells the full story. See the XSWX:GALE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Galenica Ltd is an integrated healthcare service provider in Switzerland. The business is operated from two segments Products & Care and Logistics & IT. The Products & Care segment comprises the Retail business area with offerings for patients and end customers and the Professionals business area with offerings for business customers and partners in the healthcare sector. The Logistics & IT segment comprises the two sectors Wholesale and Logistics & IT Services. These provide services for all those involved in the healthcare sector - pharmacies, drugstores, doctors, hospitals and care homes, partners, and suppliers. Geographically, it operates in Switzerland and Other Countries.
83GF Score
Get the complete analysis for XSWX:GALE
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALE has been successfully added to your 
